Every Form 4 that Aura Biosciences, Inc. (AURA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AURA filings page.
Aura Biosciences, Inc. (AURA) reported that Chief People Officer Julie Person received 107,611 shares of Common Stock in the form of restricted stock units (RSUs) as an inducement award, and a stock option for 212,389 shares with an exercise price of $7.43 per share.
The RSUs vest in four substantially equal annual installments starting September 15, 2027, conditioned on continued service. The stock option vests 25% on August 12, 2027, with the remaining 75% vesting pro-rata in 36 monthly installments, also subject to continued service, and expires on September 1, 2036.
Aura Biosciences, Inc. (AURA) reported that Chief Regulatory & Quality Officer Erica Kratz received equity awards on 2026-09-01. She was granted 100,885 restricted stock units as an inducement award, each representing one share of common stock, vesting in four substantially equal annual installments starting on September 15, 2027, subject to continued service. She also received a stock option for 199,115 shares of common stock at an exercise price of $7.43 per share, vesting 25% on August 10, 2027 with the remainder vesting pro rata in 36 monthly installments, and expiring on September 1, 2036. Following these awards, the filing reports holdings of 100,885 common shares and 199,115 stock options directly owned.
Aura Biosciences, Inc. (AURA) reported that Chief Medical Officer Janet Jill Hopkins received equity compensation awards. She was granted 58,850 RSUs, each representing one share of common stock upon vesting, and a stock option for 116,150 shares of common stock at an exercise price of $7.43 per share. The RSUs vest in four substantially equal annual installments starting September 15, 2027, and the option vests monthly over 48 months starting October 1, 2026, with an expiration date of September 1, 2036. Following these grants, she directly holds 380,190 common shares, excluding unexercised options.
Aura Biosciences, Inc. (AURA) reported that officer Amy Elazzouzi, SVP, Finance & PAO, received new equity awards. On 2026-09-01 she was granted 23,540 RSUs, each representing one share of common stock upon vesting, bringing her directly held common shares to 143,600. The RSUs vest in four substantially equal annual installments, with the first tranche vesting on September 15, 2027, subject to continued service. She was also granted a stock option for 46,460 shares of common stock at an exercise price of $7.43 per share, vesting as to 1/48th of the award monthly starting October 1, 2026, and expiring on September 1, 2036, also subject to continued service.
Aura Biosciences, Inc. (AURA) reported that Chief Operating Officer Susan Abu‑Absi received equity awards on 2026-09-01. She was granted 265,487 stock options with an exercise price of $7.43 per share, expiring on 2036-09-01, and 134,513 RSUs as an inducement award. The RSUs vest in four substantially equal annual installments starting on September 15, 2027, and the options vest 25% on August 10, 2027 with the remainder vesting pro rata in 36 monthly installments, in each case subject to continued service.
Aura Biosciences, Inc. director Jeremy Bender reported equity awards consisting of restricted stock units and stock options as part of his compensation. He received 30,000 shares of Common Stock through an RSU award, with each unit representing one share. These RSUs vest in three substantially equal annual installments beginning on July 15, 2027, subject to his continued service.
He was also granted 60,000 stock options to purchase Common Stock at an exercise price of $7.03 per share, expiring on July 7, 2036. The option vests in three substantially equal annual installments beginning on July 7, 2027, conditioned on his continued service. After these awards, he holds 30,000 shares of Common Stock and 60,000 stock options directly.
Kilroy Conor reported acquisition or exercise transactions in this Form 4 filing.
Aura Biosciences, Inc. reported that company officer Conor Kilroy received a grant of 14,858 shares of Common Stock in the form of restricted stock units (RSUs) at no cash cost. Each RSU represents one share of common stock.
The RSUs vest in two substantially equal annual installments beginning on July 15, 2027, conditioned on Kilroy’s continued service on each vesting date. Following this award, Kilroy directly holds a total of 232,693 shares of Aura Biosciences common stock.
Aura Biosciences, Inc. officer Anthony S. Gibney reported an automatic sale of common stock tied to tax withholding. On June 16, 2026, 12,824 shares were sold at $6.42 per share to cover tax obligations from vesting restricted stock units, leaving him with 265,354 directly held shares. The footnote states these sales were executed automatically and not at his discretion.
Aura Biosciences director Teresa Marie Bitetti received new equity awards as part of her compensation. She was granted 15,000 restricted stock units, each representing one share of common stock, and 30,000 stock options with an exercise price of $6.21 per share.
The RSUs and options each vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders, subject to her continued service. After the grant, she holds 36,000 shares of common stock directly, plus the newly awarded 30,000 options.
Aura Biosciences director Sapna Srivastava received new equity awards in the form of stock and options. She was granted 15,000 shares of Common Stock through a restricted stock unit (RSU) award and 30,000 stock options with an exercise price of $6.21 per share.
The RSUs and options each vest in full on the earlier of June 11, 2027 or the company’s next annual stockholder meeting, subject to her continued service. After the RSU grant, her direct Common Stock holdings total 38,500 shares, and she holds 30,000 options to buy additional shares.
Aura Biosciences, Inc. director David Michael Johnson reported new equity compensation awards and updated his holdings. He received 15,000 shares of Common Stock through a restricted stock unit (RSU) award under the 2021 Stock Option and Incentive Plan, which vests in full on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to continued service. He was also granted stock options for 30,000 shares of Common Stock at an exercise price of $6.21 per share, expiring June 11, 2036, with the same vesting schedule. After these awards, he directly holds 194,167 Common shares and 30,000 options, and indirectly holds additional shares through Velocity Capital Management LLC and the NEJ09 and NEJ12 irrevocable trusts where he is a trustee or sole member.
Aura Biosciences director Antony C. Mattessich received new equity awards. On June 11, 2026, he was granted 15,000 shares of Common Stock through a restricted stock unit award and now holds 38,500 Common Stock shares directly.
The RSUs were granted under the 2021 Stock Option and Incentive Plan, with each RSU representing one share of Common Stock. They vest in full on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to his continued service.
He was also granted stock options covering 30,000 shares of Common Stock at an exercise price of $6.21 per share. These options vest and become exercisable on the same earlier-of vesting schedule and expire on June 11, 2036.
Aura Biosciences, Inc. reported that director and officer Natalie C. Holles received significant equity awards in the form of restricted stock units, performance RSUs and stock options. She was granted 553,844 RSUs as Inducement Awards, each representing one share of common stock, vesting in four equal annual installments beginning on April 15, 2027, subject to continued service.
She also received 600,118 performance RSUs as Inducement Awards that require both time-based vesting and achievement of a performance condition. These PRSUs vest in four equal annual installments commencing on April 15, 2027 and expire on the earlier of the sixth anniversary of the grant date or the date her service with the company ends, with any unvested awards then forfeited.
In addition, Holles was granted a stock option covering 2,169,103 shares of common stock at an exercise price of $7.3900 per share, expiring on May 19, 2036. Twenty-five percent of the option vests on April 30, 2027, with the remainder vesting pro rata in 36 monthly installments, subject to continued service. Following these grants, she directly owns 1,153,962 shares of common stock.
Aura Biosciences, Inc. reported a large insider sale of its common stock connected to Matrix Capital entities. Matrix Capital Management Master Fund, LP sold 6,922,870 shares of common stock at $5.64 per share in an open-market transaction on May 7, 2026.
The shares are held by Matrix Capital Management Master Fund, LP, with Matrix Capital Management Company, LP as investment adviser and David E. Goel as managing general partner. The reporting persons indicate that the reported position is now zero shares and expressly disclaim beneficial ownership beyond any pecuniary interest.
Aura Biosciences, Inc. insider Conor Kilroy reported an open-market sale of 11,738 shares of Common Stock at a weighted average price of about $7.02 per share. According to the disclosure, these shares were sold automatically to cover tax withholding obligations from vested restricted stock units, not at Kilroy’s discretion.
After the sale, Kilroy directly holds 217,835 Aura Biosciences shares, indicating that the transaction reflects a routine tax-related disposition rather than a change in his core ownership position.
Kilroy Conor reported acquisition or exercise transactions in this Form 4 filing.
Aura Biosciences officer Conor Kilroy reported equity awards that increase his holdings. On March 2, 2026, he was granted a stock option for 112,661 shares of common stock at $0.00 per share and an award of 62,339 shares of common stock. The RSU shares vest in four equal annual installments starting January 15, 2027, while the option vests 25% on February 1, 2027 and the remainder in 36 monthly installments, all subject to continued service. After these grants, he directly owns 229,573 common shares and holds options for 112,661 shares.
Gibney Anthony S reported acquisition or exercise transactions in this Form 4 filing.
Aura Biosciences, Inc. reported that company officer Anthony S. Gibney received new equity awards. On March 2, 2026, he was granted 71,245 shares of common stock through a restricted stock unit award and a stock option for 128,755 shares.
The restricted stock units vest in four substantially equal annual installments beginning on January 15, 2027, conditioned on his continued service. The stock option vests with 25% of the shares on February 1, 2027, and the remaining shares vest pro rata in 36 monthly installments, also subject to continued service.
Aura Biosciences reported new equity awards to director and officer Elisabet de los Pinos. On March 2, 2026, she acquired 166,000 shares of Common Stock through a restricted stock unit award at a grant price of $0.0000 per share, increasing her directly held Common Stock to 575,815 shares.
She also received a stock option for 249,000 shares of Common Stock at an exercise price of $0.0000 per share, with 249,000 option shares outstanding after the award. The RSUs vest in four substantially equal annual installments beginning on January 15, 2027, and the option vests 25% on February 1, 2027, with the remainder vesting pro rata in 36 monthly installments, in each case subject to her continued service.
Separately, 127,763 Common shares are held indirectly by the Elisabet de los Pinos Revocable Trust dated April 8, 2016, of which she is a trustee.
Aura Biosciences Chief Technology Officer Mark Plavsic reported equity grants. He acquired a stock option covering 112,661 shares and 62,339 shares of common stock through a restricted stock unit award.
The RSUs vest in four equal annual installments beginning on January 15, 2027. The option vests 25% on February 1, 2027, with the remaining shares vesting pro rata in 36 monthly installments, in each case contingent on his continued service.
Aura Biosciences reported that Chief Medical Officer Janet Jill Hopkins received new equity awards. She was granted a stock option for 160,944 shares of common stock at an exercise price of $0.00 per share, classified as a grant or award acquisition.
She also acquired 89,056 shares of common stock at $0.00 per share through a restricted stock unit award, bringing her directly held common stock to 321,340 shares after the transaction. The RSUs vest in four substantially equal annual installments beginning on January 15, 2027, conditioned on continued service.
The option vests with 25% of the underlying shares vesting on February 1, 2027, and the remaining 75% vesting pro rata in 36 monthly installments, also subject to her continued service on each vesting date.
Aura Biosciences, Inc. reported that Senior Vice President, Finance, Amy Elazzouzi received new equity awards. She was granted stock options for 80,472 shares at an exercise price of $0.00 and 44,528 shares of common stock via restricted stock units, both as compensation awards.
The restricted stock units vest in four substantially equal annual installments beginning on January 15, 2027, conditioned on continued service. The stock options vest with 25% on February 1, 2027, and the remaining 75% in 36 monthly installments, also subject to continued service.
Kilroy Conor reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 12,079 shares at a weighted average price of $5.05 per share. Following the reported transactions, holdings were 167,234 shares.
Plavsic Mark reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 15,890 shares at a weighted average price of $5.05 per share. Following the reported transactions, holdings were 181,397 shares.
Hopkins Janet Jill reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 20,401 shares at a weighted average price of $5.06 per share. Following the reported transactions, holdings were 232,284 shares.
Elazzouzi Amy reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 8,549 shares at a weighted average price of $5.06 per share. Following the reported transactions, holdings were 75,532 shares.
de los Pinos Elisabet reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 47,648 shares at a weighted average price of $5.06 per share. Following the reported transactions, holdings were 409,815 shares.
Amy Elazzouzi, Senior Vice President, Finance of Aura Biosciences, Inc. (AURA), reported an insider transaction involving company common stock. On January 20, 2026, she sold 1,581 shares of common stock at $4.86 per share. According to the disclosure, these shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units, and the sales were automatic rather than discretionary. After this transaction, she beneficially owned 84,081 shares of Aura Biosciences common stock, held directly.
Aura Biosciences, Inc. director and President & Chief Executive Officer Elisabet de los Pinos reported an automatic sale of common stock to cover taxes on vesting restricted stock units. On January 20, 2026, she sold 16,928 shares of common stock at a weighted average price of $4.86 per share in multiple trades within a price range of $4.73 to $4.86. After this transaction, she beneficially owned 457,463 shares of Aura Biosciences common stock directly. An additional 127,763 shares were reported as indirectly owned through the Elisabet de los Pinos Revocable Trust, of which she is a trustee. The filing notes that the sales were solely to satisfy tax withholding obligations and were not made at her discretion.
Aura Biosciences, Inc. (AURA) reported an insider tax-related stock sale by its Chief Medical Officer. On 11/17/2025, the officer sold 17,109 shares of common stock at a weighted average price of $5.42 per share, with individual sale prices ranging from $5.42 to $5.44. The filing explains that these shares were sold automatically to cover tax withholding obligations tied to the vesting of restricted stock units, and the transactions were not at the officer’s discretion. After these sales, the reporting person beneficially owned 252,685 shares of Aura Biosciences common stock in direct ownership.
Aura Biosciences (AURA) filed a Form 4 disclosing that its Senior Vice President, Finance sold 896 shares of common stock at $6.35 on 10/29/2025. According to the filing, the sale was made to cover tax withholding obligations arising from the vesting of restricted stock units and was automatic, not at the reporting person’s discretion.
Following the transaction, the officer directly holds 85,662 shares of Aura Biosciences common stock.
Aura Biosciences (AURA) Form 4: President and Chief Executive Officer (also a Director) reported an automatic sale tied to tax withholding from RSU vesting. On 10/29/2025, the reporting person sold 9,049 shares of common stock at $6.35 per share (Transaction Code S).
Following the transaction, beneficial ownership was 474,391 shares held directly and 127,763 shares held indirectly through the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016. The filing notes the sale was executed solely to satisfy tax obligations and not at the reporting person’s discretion.
Aura Biosciences (AURA) reported an insider transaction by its Chief Technology Officer. On 10/16/2025, the officer sold 12,169 shares of common stock at $6.35 per share. Following the sale, the officer directly held 197,287 shares.
The filing states the sale was executed to cover tax withholding obligations upon the vesting of restricted stock units and was automatic, not at the officer’s discretion.